TK-002 (takisbiotech)

N/A

Report date: 2026/04/08 20:02:35

Base Information

Drug NameTK-002 (takisbiotech)

Drug Alias NameTK-002

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-Receptor tyrosine-protein kinase erbB-3Anti-CD3

TargetsReceptor tyrosine-protein kinase erbB-3T cell surface glycoprotein CD3

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryItaly

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesTakis

China Registration ClassN/A

Develop Information

Active CompaniesTakis

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A